·       “Inhibition of the platelet Glycoprotein II b/III a receptor with tirofiban in unstable angina and Non Q-Wave Myocardial Infarction”.  (PRISM study )  NEJM vol.338 No.21, 1998.

·       “A comparation of aspirin plus tirofiban with aspirin plus heparin for unstable angina”.  ( PRISM PLUS study ) NEJM vol. 338 No. 21, 1998

·       “ Estudio multicéntrico, aleatorio, entre pacientes y grupos paralelos para comparar la eficacia y tolerabilidad de Valsartan 80 mg una vez al día y Enalapril 20 mg una vez al día, según la altitud sobre el nivel del mar ( 2600mt-1538mt-100mt ) en pacientes con hipertensión arterial esencial no complicada, leve a moderada, tratados por ocho semanas y evaluar, comparar, la tolerabilidad de ambos medicamentos como monoterapia y en combinación con indapamida 1.25mg una vez al día”. international journal of cardiology 2000; 72: 247-254

 ·      An open labeled, randomized, parallel dose finding study of TNK-tPA in combination with AGRASSTAT in the treatment of acute myocardial infarction (FASTER)

·       “ A Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy Of Eplerenone In Patients With Heart Failure Following Acute Myocardial Infarction “ (EPHESUS)  NEJM 2003; 348:1309-1321

·       Estudio abierto, randomizado, de grupo paralelo, multicéntrico, para comparar la eficacia y seguridad de rosuvastatina 10 mg una vez al dia, en pacientes con hipercolesterolemia tipos IIa y IIb Nº D 356OL00018 (DISCOVERY PENTA)

·       An 8 week double blind, multicenter, randomized, multifactorial,placebo-controlled,parallel group study to evaluate the efficacy and safety of aliskiren administred alone and in combination with hydrochlorotiazide in patients with essential hipertensión. CSPP100A2204.

·       Protocolo BAY 59-7939 11223 / 11223 ODIXa-DVT  “Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep Vein Thrombosis. ODIXa-DVT”.Circulation 2007;116 pp180-187

·       Protocolo “SEACOAST” The safety and Efficacy of a Combination of      Niacin ER and Simvastatin in patients w ith Dyslipidemia

·       “A 36 week,randomized,double blind, multicenter,parallel group study comparing te efficacy and safety of aliskiren in combination with losartan compared to losartan on te regresión of left ventricular hypertrophy in overweight patients with essential hypertension, ALLAY. Circulation 2009; 119(4) pp 530-539

·       RECORD 2 Study: Regulation of coagulation in orthopedic surgery to prevent DVT and PE, controlled, double blind, randomized study of BAY 59-7939 in the extended prevention of VTE in patients undergoing elective total hip replacement. Kakkar AK, Brenner B, Dahl OE, et al, for the RECORD2 investigators.Lancet  Volume 372, Issue 9632, Pages 31 - 39

·       RECORD 3/ Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358(26):2776-2786.

·       “JUPITER” A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase 3 Study of Rosuvastatin (CRESTOR®) 20 mg in the Prevention of Cardiovascular Events Among Subjects With Low Levels of LDL Cholesterol & Elevated Levels of C- Reactive Protein. Ridker PM. New Engl J Med 2008; 359: 2195-2207
 
·       Multinational, randomized, double blind, placebo-controlled, forced-titration, 2x2 factorial design study of the efficacy and safety of long term administration of diabetes and cardiovascular outcomes in subjects with impaired glucose tolerance (NAVIGATOR) NEJM 2010;  362:1463-1476.

·       Multinational, randomized, double blind, placebo-controlled, forced-titration, 2x2 factorial design study of the efficacy and safety of long term administration of diabetes and cardiovascular outcomes in subjects with impaired glucose tolerance (NAVIGATOR) NEJM 2010;  362:1477-1490.

·       A Prospective, Randomized, Double-Blind, Parallel-Group, Multicenter, Non-inferiority Study Comparing the Efficacy and Safety of Rivaroxaban (BAY 59-7939) With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation (ROCKET-AF) NEJM 2011; 365: 883-891.

·      (Apixaban Versus Acetylsalicylic Acid [ASA] to Prevent    Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment.AVERROES. New england journal of medicine February 10, 2011

·       An internacional. Multicenter, randomized, double blind, double dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E (3.0 mg s.c. once weekly) versus oral INR adjusted warfarin in i.e. treatment of patients with symptomatic pulmonary embolism, with or without symptomatic deep venous thrombosis” (CASSIOPEA)

·       A phase 2b, randomized, multicenter, dose ranging study assessing the safety and efficacy of pd 0348292 in the prevention of venous thromboembolic events (vte) in subjects undergoing an elective, unilateral total knee replacement. (ADVANCE 2). The Lancet, Volume 375, Issue 9717, Pages 807 – 815. March 2010

·       A randomized, double-blind, triple-dummy, dose-ranging study, including an active control of  unfractionated heparin and eptifibatide, to evaluate the clinical efficacy and safety of otamixaban,  in patients with non-ST elevation acute coronary syndrome and planned early invasive strategy  STUDY NUMBER: DRI6624 [XRP0673A/2003] SEPIA-ACS 1/TIMI 42. The Lancet, Volume 374, Issue 9692, Pages 787 – 795. Sep 2009

·       A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation (ARISTOTLE). NEJM 2011; 365: 981-992, sept 2011

·       Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in High Risk People with Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT), or Early Type 2 Diabetes Mellitus: The ORIGIN Trial (Outcome Reduction with Initial Glargine Intervention)” (Outcome Reduction with an  Initial Glargine Intervention ) N Engl J Med 367;4 july 26, 2012
 
·       A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events. (TRA 2°P - TIMI 50). N Engl J Med 2012;366:1404-13.

·       Protocolo P04736 “Estudio multicéntrico, aleatorizado, a doble ciego, controlado con placebo para evaluar  la seguridad y eficacia de SCH 530348 en combinación con el tratamiento estándar en sujetos con  síndrome coronario agudo: Antagonista del receptor de la trombina para la reducción de eventos  clínicos en el síndrome coronario agudo (TRACER), Thrombin Receptor Antagonist for Clinical  Event  Reduction in Acute Coronary Syndrome)”. N Engl J Med 2012;366:20-33.

 ·      A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coronary Syndromes. ATLAS 2. N Engl J Med 2012;366:9-19.

 
·       A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine Whether, in Patients With Type 2 Diabetes at High Risk for Cardiovascular and Renal Events, Aliskiren, on Top of Conventional Treatment, Reduces Cardiovascular and Renal Morbidity and Mortality. ALTITUDE. N Engl J Med Med 2012;367:2204-13

·       A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of Edoxaban (DU-176b) Versus Warfarin In Subjects With Atrial Fibrillation - Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48). N Engl J Med 2013;369:2093-104.

·       "A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy in Patients with Clinically Evident Cardiovascular Disease".

·       A Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Safety and Efficacy of AMG 145 in Combination With Statin Therapy in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia.

·       A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effect of SAR236553/REGN727 on the occurrence of cardiovascular events in patients who have recently experienced an Acute Coronary Syndrome.

·       “A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Exenatide once weekly in Patients with Type 2 Diabetes Mellitus (EXenatide Study of Cardiovascular Event Lowering Trial (EXSCEL))”

·       Protocolo BAY 59-7939 11223 / 11223 ODIXa-DVT  “Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute  Symptomatic Deep Vein Thrombosis. ODIXa-DVT”.Circulation 2007;116 pp180-187

·       "Medically lll Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER)", (the "Study"